Heterogeneous induction of microglia M2a phenotype by central administration of interleukin-4

Journal of Neuroinflammation

Volumn 11, Issue 1, 2014, Pages

  Pepe, Giovanna ^a   Calderazzi, Giorgia ^a   De Maglie, Marcella ^a   Villa, Alessandro Maria ^a   Vegeto, Elisabetta ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

alternative activation; centrally administered interleukin 4; M2 polarization; microglia

Indexed keywords

INTERLEUKIN 4; MESSENGER RNA; RECOMBINANT INTERLEUKIN 4; TISSUE EXTRACT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASSAY; BRAIN THIRD VENTRICLE; CELL SUBPOPULATION; CONTROLLED STUDY; CORPUS STRIATUM; FRONTAL CORTEX; GENE CONTROL; GENE INDUCTION; IMMUNOCHEMISTRY; MACROPHAGE; MALE; MICROGLIA; MICROGLIA M2A; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; POLARIZATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; C57BL MOUSE; CELL POLARITY; DRUG EFFECTS; FRONTAL LOBE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; NEOSTRIATUM; PHYSIOLOGY;

ANIMALS; CELL POLARITY; FRONTAL LOBE; INJECTIONS, INTRAVENTRICULAR; INTERLEUKIN-4; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; NEOSTRIATUM; PHENOTYPE; RNA, MESSENGER;

EID: 84924919322     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-014-0211-6     Document Type: Article

References (40)

1. Saijo K, Glass CK: Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol 2011, 11:775-787.
2. Colton CA: Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol 2009, 4:399-418.
3. Castano A, Herrera AJ, Cano J, Machado A: Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 1998, 70:1584-1592.
4. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT: Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
5. Qin L, Liu Y, Hong JS, Crews FT: NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Glia 2013, 61:855-868.
6. Neniskyte U, Vilalta A, Brown GC: Tumour necrosis factor alpha-induced neuronal loss is mediated by microglial phagocytosis. FEBS Lett 2014, 588(17):2952-2956.
7. De Pablos RM, Herrera AJ, Villaran RF, Cano J, Machado A: Dopamine-dependent neurotoxicity of lipopolysaccharide in substantia nigra. FASEB J 2005, 19:407-409.
8. Vroon A, Drukarch B, Bol JG, Cras P, Breve JJ, Allan SM, Relton JK, Hoogland PV, Van Dam AM: Neuroinflammation in Parkinson's patients and MPTP-treated mice is not restricted to the nigrostriatal system: microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb. Exp Gerontol 2007, 42:762-771.
9. Hanisch UK: Functional diversity of microglia - how heterogeneous are they to begin with? Front Cell Neurosci 2013, 7:65.
10. Lawson LJ, Perry VH, Dri P, Gordon S: Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990, 39:151-170.
11. de Haas AH, Boddeke HW, Biber K: Region-specific expression of immunoregulatory proteins on microglia in the healthy CNS. Glia 2008, 56:888-894.
12. van Weering HR, Boddeke HW, Vinet J, Brouwer N, de Haas AH, van Rooijen N, Thomsen AR, Biber KP: CXCL10/CXCR3 signaling in glia cells differentially affects NMDA-induced cell death in CA and DG neurons of the mouse hippocampus. Hippocampus 2011, 21:220-232.
13. Scheffel J, Regen T, Van Rossum D, Seifert S, Ribes S, Nau R, Parsa R, Harris RA, Boddeke HW, Chuang HN, Pukrop T, Wessels JT, Jürgens T, Merkler D, Brück W, Schnaars M, Simons M, Kettenmann H, Hanisch UK: Toll-like receptor activation reveals developmental reorganization and unmasks responder subsets of microglia. Glia 2012, 60:1930-1943.
14. Fitzner D, Schnaars M, van Rossum D, Krishnamoorthy G, Dibaj P, Bakhti M, Regen T, Hanisch UK, Simons M: Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis. J Cell Sci 2011, 124:447-458.
15. Pannell M, Szulzewsky F, Matyash V, Wolf SA, Kettenmann H: The subpopulation of microglia sensitive to neurotransmitters/neurohormones is modulated by stimulation with LPS, interferon-γ, and IL-4. Glia 2014, 62:667-679.
16. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS: Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 2000, 20:6309-6316.
17. Vegeto E, Belcredito S, Etteri S, Ghisletti S, Brusadelli A, Meda C, Krust A, Dupont S, Ciana P, Chambon P, Maggi A: Estrogen receptor-α mediates the brain antiinflammatory activity of estradiol. Proc Natl Acad Sci USA 2003, 100:9614-9619.
18. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686.
19. Cherry JD, Olschowka JA, O'Banion MK: Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation 2014, 11:98.
20. Whitton PS: Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007, 150:963-976.
21. Vegeto E, Cuzzocrea S, Crisafulli C, Mazzon E, Sala A, Krust A, Maggi A: Estrogen receptor-α as a drug target candidate for preventing lung inflammation. Endocrinology 2010, 151:174-184.
22. GraphPad Prism. [http://www.graphpad.com/scientific-software/prism/]
23. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP: Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation 2006, 3:27.
24. Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M: Microglia acquire distinct activation profiles depending on the degree of α-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One 2010, 5:e8784.
25. Schmid CD, Melchior B, Masek K, Puntambekar SS, Danielson PE, Lo DD, Sutcliffe JG, Carson MJ: Differential gene expression in LPS/IFNγ activated microglia and macrophages: in vitro versus in vivo J Neurochem 2009, 109(Suppl 1):117-125.
26. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA: Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014, 41:14-20.
27. Romo N, Magri G, Muntasell A, Heredia G, Baia D, Angulo A, Guma M, Lopez-Botet M: Natural killer cell-mediated response to human cytomegalovirus-infected macrophages is modulated by their functional polarization. J Leukoc Biol 2011, 90:717-726.
28. Liao B, Zhao W, Beers DR, Henkel JS, Appel SH: Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol 2012, 237:147-152.
29. Lewis KE, Rasmussen AL, Bennett W, King A, West AK, Chung RS, Chuah MI: Microglia and motor neurons during disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis: changes in arginase1 and inducible nitric oxide synthase. J Neuroinflammation 2014, 11:55.
30. Kumar A, Stoica BA, Sabirzhanov B, Burns MP, Faden AI, Loane DJ: Traumatic brain injury in aged animals increases lesion size and chronically alters microglial/macrophage classical and alternative activation states. Neurobiol Aging 2013, 34:1397-1411.
31. He Q, Yu W, Wu J, Chen C, Lou Z, Zhang Q, Zhao J, Wang J, Xiao B: Intranasal LPS-mediated Parkinson's model challenges the pathogenesis of nasal cavity and environmental toxins. PLoS One 2013, 8:e78418.
32. Doorn KJ, Lucassen PJ, Boddeke HW, Prins M, Berendse HW, Drukarch B, van Dam AM: Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease. Prog Neurobiol 2012, 98:222-238.
33. Frank-Cannon TC, Tran T, Ruhn KA, Martinez TN, Hong J, Marvin M, Hartley M, Treviño I, O'Brien DE, Casey B, Goldberg MS, Tansey MG: Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 2008, 28:10825-10834.
34. Gadani SP, Cronk JC, Norris GT, Kipnis J: IL-4 in the brain: a cytokine to remember. J Immunol 2012, 189:4213-4219.
35. Jacobs AH, Tavitian B: Noninvasive molecular imaging of neuroinflammation. J Cereb Blood Flow Metab 2012, 32:1393-1415.
36. Stutz AM, Pickart LA, Trifilieff A, Baumruker T, Prieschl-Strassmayr E, Woisetschlager M: The Th2 cell cytokines IL-4 and IL-13 regulate found in inflammatory zone 1/resistin-like molecule α gene expression by a STAT6 and CCAAT/enhancer-binding protein-dependent mechanism. J Immunol 2003, 170:1789-1796.
37. Gray MJ, Poljakovic M, Kepka-Lenhart D, Morris SM Jr: Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPβ. Gene 2005, 353:98-106.
38. H 2 cytokines and allergic challenge induce Ym1 expression in macrophages by a STAT6-dependent mechanism. J Biol Chem 2002, 277:42821-42829.
39. -/- mice is correlated with decreased central nervous system inflammation and reduced numbers of cells with alternatively activated macrophage phenotypes in a murine model of neurocysticercosis. Infect Immun 2011, 79:2586-2596.
40. Murray PJ, Wynn TA: Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol 2011, 89:557-563.